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ABSTRACT 
Treatment strategy for retinopathy of prematurity (ROP) includes anti-vascular endothelial growth factor (anti-VEGF) 
and/or laser therapy. The aim of this study was to investigate the clinical effects of topical Coqun® eye drop (CoQ10 and 
Vitamin-E) on the progression and treatment of ROP. One hundred and ten infants with type 1 ROP who received 
Coqun® (Coqun group) and 131 infants with type 1 ROP who did not receive Coqun® (control group) were included in this 
retrospective analysis. All patients were follow-up until retinal vascular maturation was complete. Intravitreal 
bevacizumab (IVB) injection or laser photocoagulation (LPC) were apply if needed. Treatment frequency, treatment 
response and mean follow-up time were compare. The number of IVB was similar between the groups, but infants in the 
Coqun group underwent significantly fewer LPC procedure than those in the control group (P = 0.022). The mean follow-
up time was significantly shorter in infants receiving Coqun® in stage 1 ROP (P = 0.017) and similar in stages 2-4 ROP and 
aggressive posterior retinopathy of prematurity (APROP). The number of LPC procedure was fewer in the Coqun group in 
APROP (P = 0.043). These results indicate that faster retinal vascular maturation in infants with low-grade ROP and lower 
number of treatments with APROP could be achieve with Coqun® therapy. 
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INTRODUCTION
Retinopathy of prematurity (ROP) is an oxidative-stress-
related disease of incompletely vascularized retina of the 
low birth weight and premature infants. Prompt 
diagnosis and early management is critical to prevent 
blindness [1, 2]. Recent technical advancements in the 
neonatal intensive care units have markedly improved 
the survival rates of low birth weight infants and hence 
increased the incidence of ROP worldwide [3]. 
Retinopathy of prematurity is a multifactorial disease and 
low birth weight, low birth week and oxygen 
dysregulation are among the most significant risk factors 
[4, 5]. If ROP is left untreated, it may lead to vision-
threatening complications such as ectopic macula, retinal 
detachment, angle-closure glaucoma or pupillary block. 
Even though, it may result in long-term sequelae such as 
myopia, strabismus or amblyopia [2, 6]. 
The association between hyperoxia and ROP has long 
been known. Premature infants are at increased risk of 
oxidative stress due to immature antioxidant systems [7]. 
Oxidative stress induced free oxygen radicals contribute 
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to mitochondrial and electron transport chain (ETC) 
dysfunction and cause ischemic damage which is one of 
the main mechanisms underlying ROP development [8]. 
Coenzyme Q10 (CQ10, Ubiquinone), an important 
cofactor in ETC, is a potent antioxidant shown to have 
protective effects in experimental animal models of 
retinopathy and in neurodegenerative disorders such as 
Alzheimer's and Parkinson's diseases [9-12]. 
We have recently investigated the efficacy of Coqun® 
(Visufarma, Rome), which contains CQ10 and Vitamin E 
on the thiol-disulphide homeostasis, a novel oxidative 
stress marker in the ROP disease course [13]. To the best 
of our knowledge, there is no study on the clinical effects 
of CQ10 in premature infants. In this study, we sought to 
evaluate the effects of Q10/Vitamin E combination 
coenzyme on the progression and treatment of ROP. 
METHODS 
We retrospectively reviewed the records of premature 
infants admitted to ROP department of ophthalmology 
clinic between February 2016 and February 2017 in Bursa 
Yuksek Ihtisas Health Science University, Bursa, Turkey. 
Infants with a ROP diagnosis at any stage who received 
Coqun® were included in the study. The protocol was 
approved by the Ethics Committee of HSU Bursa Yuksek 
Ihtisas Training and Research Hospital (2011-KAEK 
2018/08.06). Moreover, the study adhered to the tenets 
of the Declaration of Helsinki. 
All infants born below 37 weeks of gestational age (GA) 
were examined. Those with a ROP diagnosis whose 
parents’ consent was obtained to receive Coqun® were 
assigned into the Coqun group and those who had a ROP 
diagnosis but did not receive Coqun® were assigned to 
the control group. The first ROP examination of infants 
with a GA of ≤ 27 weeks was performed at 30-31 weeks 
and of those with a GA of ≥ 28 weeks was done 4 weeks 
after birth. Infants who already had a ROP diagnosis 
and/or were already receiving ROP treatment, those with 
stage 5 ROP, anterior segment disorders or a congenital 
anomaly, systemic complications such as sepsis, acidosis, 
intraventricular hemorrhage, an indistinguishable fundus 
appearance and those who continued their treatment in 
another center were excluded. 
Oral feeding was discontinued one hour before 
ophthalmic examination and 0.5% tropicamide 
(Tropamid® Bilim Pharmaceuticals, Turkey) and 2.5% 
phenylephrine (Mydfrine®, Alcon, USA) eye drops were 
administered to achieve and maintain pupil dilation. 
Thereafter, a sterile lid speculum was placed under 
topical anesthesia using proparacaine hydrochloride 
(Alcaine®, Alcon, USA). The anterior segment, optic disc 
and macula were evaluated using a +28 diopter lens and 
indirect binocular ophthalmoscopy (Omega 500, Heine, 
Germany). Peripheral retinal examination was extended 
to the ora serrata using a scleral depressor.  All retinal 
images were recorded with an Archimed Medical video 
archiving system (Pronova, Turkey). The use of Coqun® 
was recommended twice a day one drop for infants with 
a ROP diagnosis of any stage until retinal vascularization 
reached the ora serrata. 
We used the Early Treatment of Retinopathy of 
Prematurity (ETROP) criteria to make a treatment 
decision and the International Classification of 
Retinopathy of Prematurity (ICROP) categorization to 
classify ROP [14, 15]. Accordingly, infants with stages 0-1 
ROP were classified as Group 1, stages 1-2 ROP as Group 
2, infants with at least 2 clock hours of stage 3 ROP or 
stage 4 ROP as Group 3 and those with aggressive 
posterior retinopathy of prematurity (APROP) (it is 
characteristically in a more posterior location with rapid 
progression of stage 1 to 5 and poor prognosis) [16] were 
classified as Group 4.  
Treatment was consider for eyes with zone I stage 1-2 
plus disease, zone II stage 2-3 plus disease and for infants 
with APROP. Based on the BEAT-ROP study criteria, we 
used Intravitreal bevacizumab (IVB) (Altuzan®, Roche, 
Switzerland) 0.16-0.32 mg (very low-low dose) injection 
as the first-line treatment [17, 18]. IVB was performed in 
the operating room under local anesthesia (0.5% 
propacaine hydrochloride drop (Alcaine®, Alcon, USA) 
using a 32-gauge needle placed into the vitreous cavity 
0.5-1 mm posterior to the limbus. The anti-VEGF dose in 
groups 1, 2 and 3 was 0.16 mg and in group 4 (AP-ROP) 
0.32 mg. Infants who did not respond to anti-VEGF 
treatment, i.e. if ROP did not regress and/or progress 
within two weeks after the treatment, were treated with 
diode laser photocoagulation (LPC). 
Laser photocoagulation was performed in the operating 
room under general anesthesia using an 810-nanometer 
(nm) diode laser (Iridex; Oculight SL, USA) and by leaving 
a half-shoot space (150–200 milliwatt [mW] of power for 
0.2 second [s]). Infants who were treated with LPC 
received netilmicin sulfate 3% (Netira®, Teka, Turkey) 
and dexamethasone (Maxidex, Alcon, USA) eye drops 
every 6 hours one drop for one week. Those who were 
treated with anti-VEGF injection received netilmicin eye 
drops every six hours one drop and betaxolol 
hydrochloride eye drop (Betoptic-s®, Alcon, USA) once-a-
day for one week. Follow-up was conducted at 
postoperative days 1, 3 and 7. The efficiency of anti-VEGF 
treatment was assessed one week after the procedure 
and of LPC treatment at postoperative weeks 2 to 5. The 
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frequency of follow-up varied depending on the physical 
examination findings. 
Infants who received anti-VEGF treatment, those who 
were treated with LPC as well as those who did not 
receive any treatment were followed-up until retinal 
vascularization was complete. Similarly, Coqun®, twice-a-
day one drop, was continued until retinal vascularization 
was complete. 
Gestational age, birth weight (BW), length of stay in the 
incubator, follow-up time, anterior segment and fundus 
examination findings, localization and stage of ROP and 
presence of a plus disease as well as the treatment 
procedure were recorded. We compared ROP stages, 
treatment frequency, treatment response and mean 
follow-up time between the two groups. 
Statistical analysis was performed using SPSS Version 
18.0 (SPSS, Inc., IL, USA). We used Kolmogorov-Smirnov 
test to assess normality of distribution. For normally 
distributed data, comparison between the two groups 
was performed using independent samples t-test, and for 
abnormally distributed data the Mann Whitney U test. 
Statistical significance was set at a P-value of < 0.05 and 
confidence interval of 95%. 
RESULTS 
A total of 482 eyes of 241 infants were included in the 
study. Of these 110 (58 females, 52 males) were assigned 
in the Coqun® group and 131 (61 females, 70 males) in 
the control group. The mean ± standard deviation (SD) of 
GA in the Coqun® and control groups were 29.33 ± 2.87 
(range, 23-35) weeks and 29.14 ± 2.89 (range, 23-34) 
weeks, respectively. Groups were well matched 
regarding GA and gender (P = 0.43 and P = 0.36). The 
average birth weights, the mean follow-up times and the 
mean length of stay in the incubator times were similar 
between the two groups (P = 0.62, P = 0.13 and P = 0.73, 
respectively).  
 
Table 1. Demographics of the Patients in Coqun and Control Groups. 
 Coqun® Control P-value 
Sex   0.36 
Male; n 52 70  
Female; n 58 61  
GA, weeks; Mean ± SD 29.33 ± 2.87 29.14 ± 2.89 0.43 
BW, g; Mean ± SD 1255.41 ± 445.55 1291.84 ± 475.45 0.62 
Incubator time, days; Mean ± SD 49.7 ± 32.1 51.3 ± 32.2 0.73 
Follow-up time, weeks; Mean ± SD 48.82 ± 7.31 50.59 ± 7.65 0.13 
Anti-VEGF injection; n (%) 26 (23.6) 30 (22.9) 0.65 
Laser photocoagulation; n (%) 12 (10.9) 32 (24.4) 0.022 
Abbreviations: SD: standard deviation; GA: Gestational age; BW: Birth weight; n: number; %: percentage; g: gram; Anti-VEGF: anti-vascular endothelial growth factor; Coqun: 
topical Coqun® eye drop (CoQ10 and Vitamin-E). P < 0.05: Statistically difference in laser photocoagulation numbers between the groups. 
 
Table 2. Subgroup Analyses in the Coqun® and Control Groups 
 Coqun® (+) Control P-value 
Group 1 (n = 42/45)    
GA at birth (weeks) 30.62 ± 2.56 30.53 ± 2.56 0.87 
Birth weight (g) 1487.1 ± 441.3 1512.8 ± 540.1 0.93 
Follow-up time (weeks) 44.95 ± 5.71 47.26 ± 5.67 0.017 
Group 2 (n = 35/38)    
GA at birth (weeks) 29.14 ± 2.55 29.89 ± 2.05 0.16 
Birth weight (g) 1247.5 ± 420.1 1303.8 ± 377.7 0.37 
Follow-up time (weeks) 50.85 ± 7.09 52.02 ± 8.58 0.66 
Group 3 (n = 15/19)    
GA at birth (weeks) 28.26 ± 2.73 29.84 ± 2.85 0.13 
Birth weight (g) 1112.3 ± 419.8 1270.3 ± 462.5 0.29 
Follow-up time (weeks) 48.50 ± 8.88 53.76 ± 8.47 0.31 
Group 4 (n = 18/29)    
GA at birth (weeks) 26.44 ± 2.17 26.41 ± 2.16 0.96 
Birth weight (g) 862.2 ± 233.3 954.9 ± 269.2 0.25 
Follow-up time (weeks) 54.72 ± 6.24 53.53 ± 6.73 0.67 
Data in table are presented as Mean ± SD. 
Abbreviations: SD: standard deviation; n: number; GA: Gestational age; g: gram; Coqun: topical Coqun® eye drop (CoQ10 and Vitamin-E). P < 0.05: Statistically difference in 
follow-up time between the groups. 
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Figure 1. The number of treated and untreated infants in the subgroup analysis 
 
Group 1: infants with stages 0-1 ROP; Group 2: infants with stages 1-2 ROP; Group 3: infants with at least 2 clock hours of stage 3 ROP or stage 4 ROP; 
Group 4: infants with aggressive posterior retinopathy of prematurity (APROP). IVB: Intravitreal bevacizumab; LPC: Laser photocoagulation; Coqun: 
topical Coqun® eye drop (CoQ10 and Vitamin-E). The culumns represent the number of infants. 
 
Demographic data is shown in Table 1. Subgroup analysis 
showed no significant difference in mean GA and mean 
BW between any of the groups (Table 2). The mean 
follow-up time was statistically shorter in infants 
receiving drug treatment in Group 1 (P = 0.017) but it 
was not statistically significant between other groups (P = 
0.66, P = 0.31, P = 0.67) (Table 2). 
The number of untreated infants in the Coqun® and 
control groups were 72 (65.5%) and 69 (52.7%), 
respectively. The number of infants who received an 
intravitreal injection in the Coqun® and control groups 
were 26 (23.6%) and 30 (22.9%), respectively. Infants in 
the control group underwent significantly more Diode 
LPC procedures than those in the Coqun® group [32 
(24.4%) versus 12 (10.9%); P = 0.022].  
The number of treated and untreated infants in the 
subgroup analysis are presented in Figure 1. Accordingly, 
in Group 1, retinal maturation was complete in all infants 
in the Coqun® and control groups without any IVB or LPC 
treatment. In Group 2, the number of infants who 
received any means of treatment was 7 in the Coqun® 
and 15 in the control groups (P = 0.19) and in Group 3, 13 
in the Coqun® and 18 in the control groups (P = 0.33). In 
Group 4, while the number of infants treated with IVB 
was equal in the both groups, significantly more infants 
underwent LPC in the control group than the Coqun® one 
(15 versus 4; P = 0.043). 
DISCUSSION 
In the current study, we found that the use of 
Q10/Vitamin E combination coenzyme provided faster 
retinal maturation with fewer treatments in infants with 
ROP.  
The pathophysiology of ROP is characterized by a two-
phase process. In phase-1, the outer retinal layers are 
not yet developed, thus retinal metabolic activity is low. 
During the first weeks of birth, the infant is exposed to an 
increased oxygen pressure due to a transition from 
intrauterine to extrauterine environment. Given the 
intrauterine physiologic hypoxic status, this transition 
causes a relative hyperoxia which is further complicated 
by assisted ventilation, used to keep the infant alive [19, 
20]. During this phase, development of retinal vessels is 
retracted and the endothelium is damaged secondary to 
hyperoxia-induced increase in free radical production 
and decrease in growth factor concentrations such as 
VEGF, Hypoxia-inducible factor 1-alpha (HIF-1α) and 
Insulin-like growth factor 1 (IGF-1) [21]. Angiogenesis of 
the peripheral avascular areas of the retina is thus 
incomplete during this phase [22]. Phase II, is called as 
hypoxic phase, which starts usually around week 32-34 
and continues until the 44th gestational week [23]. 
During this phase, metabolic activity of retina is 
increased to support development of outer segments of 
photoreceptors in the retina, a process that requires 
supplemental oxygen and is therefore associated with 
hypoxia which, in turn, triggers the secretion of a number 
of angiogenic factors such as VEGF, that causes preretinal 
proliferation at the vascular/avascular retinal border 
[23]. The jack/stat signaling pathways causing an increase 
in free radical concentration are stimulated in the both 
phases [21]. 
Excessive production of oxidative radicals or impaired 
antioxidant defense systems may lead to disruption of 
delicate oxidant-antioxidant balance, resulting in 
oxidative stress and damage. Maintaining this balance in 
the premature infant is challenging because increased 
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levels of oxidants associated with hypoxia, hyperoxia or 
inflammation cannot be counteracted by immature 
antioxidant defense systems. Studies consistently have 
shown that the antioxidant enzyme systems were 
improved and lipid peroxidation was reduced with 
increased GA [24]. One such study demonstrated that 8-
hydroxy 2-deoxy guanosine level, an indicator of 
oxidative stress, was higher in preterm infants than term 
ones [25]. The risk of ROP development in premature 
infants is negatively correlated with GA. 
CoQ10, a potent lipophilic antioxidant and membrane 
stabilizer involved in cell signal transduction and gene 
expression, is an important component of the 
mitochondrial respiratory chain as an electron carrier 
[26]. Previous studies have demonstrated the protective 
effects of coenzyme Q10 on various experimental disease 
models such as glaucoma and hypoxic neonatal rat 
models and neurodegenerative disorders [9-12, 27-29]. 
Beharry et al. [19, 29] in two recent experimental rat 
models of neonatal hypoxia showed that CoQ10 and n-3 
polyunsaturated fatty acid supplementation reduced 
intermittent hypoxia-induced oxidative stress, 
normalized retinal layers and altered factors that 
influence postnatal growth. Specifically, in a rat model of 
oxygen-induced ROP, they showed that CoQ10 reduced 
VEGF, preserved astrocytic integrity, reduced 
neovascularization and normalized retinal layers. The 
authors suggested that CoQ10 and n-3 polyunsaturated 
fatty acid supplementation could be an alternative 
supportive means of ROP treatment [12, 29]. In another 
rat model, CoQ10 eye drops were shown to protect 
retinal ganglion cells from apoptosis [30]. 
Coqun® eye drop has recently been approved for clinical 
use. Fato et al. [31] in a study on patients who received 
Coqun® one hour before pars plana vitrectomy, provided 
convincing evidence that Coqun® penetrated the vitreous 
cavity and reached the retinal layers. Several other 
studies showed that Coqun® significantly reduced 
superoxide dismutase levels in infants with 
pseudoexfoliative glaucoma and also had a positive 
effect on infants with pattern electroretinogram (internal 
retinal functions) and visual evoked potential (VEP) in 
primary open angle glaucoma [32, 33]. 
Our study had some limitations, such as the retrospective 
design and the relatively small sample. Thus, we suggest 
future investigations with larger study groups and 
prospective design to achieve more conclusive results. 
We hope this study would be a prototype for further 
studies about supplemental anti-oxidative topical 
therapy in addition to conventional ROP treatment. 
CONCLUSION 
In the current study, we showed that Coqun® provided 
faster retinal vascular maturation in infants with low-
grade ROP and reduced the number of treatments in 
infants with APROP. This appears compatible with the 
biological effects of the CQ10 and Vitamin E complex 
which is shown to support antioxidant defense systems 
and suppress toxic effects of the free oxygen radicals in 
premature infants and thereby reduce the incidence of 
ROP. Given the fact that this study is limited by its small 
sample size and its retrospective nature, our results 
should be supported by further prospective multi-center 
studies with larger and more homogenous samples to 
help development of new supportive therapeutic 
modalities in the treatment of ROP. 
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